The 4D bioprinting market is anticipated to grow at a CAGR of around 35% by 2035, claims Roots Analysis

Owing to organ scarcity and lesser number of donors, the demand for tissue engineering and organ reconstruction has increased notably; as a result, the adoption of advanced 4D bioprinting technology is anticipated to increase over the coming years

Roots Analysis has announced the addition of “4D Bioprinting Market, 2023-2035” report to its list of offerings.

4D bioprinting which involves the fourth spatio-temporal frame has diverse applications, including its use in drug regeneration and dynamic bio-constructs which can alter their shape with time. It has proven to be beneficial for research and development in the biopharmaceutical and healthcare industries. Presently, several players having dedicated facilities, cutting-edge machinery, and production lines, are engaged in the development of 4D bioprinters and smart biomaterials. In addition to the ability to morph, structures from 4D printing, have the ability to self-repair and can adapt to various environmental changes.

Key Market Insights

Currently, close to 60% of the 4D bioprinters are commercially available in the market
Of these, over 45% of the 4D bioprinters are based on laser-based technology, followed by products based on polymer-based technology (20%). Further, about 60% of the 4D bioprinters use polymer as a biomaterial.

Around 40% of the players developing smart biomaterials, are headquartered in Europe
The market is currently dominated by the presence of large players (57%); of these, interestingly all the players have been established before 1980. Interestingly 68% of smart biomaterials developed in Europe are made up of polymers; of these close to 55% have already been commercialized.

Publications related to the 4D bioprinting domain have been observed to grow at a CAGR of 130%, since 2016
Around 55% of the articles focused on 4D bioprinting were research articles, of these, more than 20% of the publications have been published in 2022. Further, popular journals that have published multiple articles include Polymers, Frontiers in Bioengineering and Biotechnology, and Micromachines Gels.

Europe and Asia-Pacific are anticipated to capture a larger share (53%) of the market, by 2035
In addition, in terms of type of technology, the market is anticipated to be primarily driven by the laser-based technology capturing more than 35% of the market. Further, biomedical applications are expected to occupy a larger segment, sharing around 65% of the overall market, by 2035.

To request a sample copy / brochure of this report, please visit
https://www.roots****ysis.com/....reports/4d-bioprinti

Key Questions Answered

 What is meant by 4D Bioprinting?
 How does 4D bioprinting work?
 What are the benefits of 4D Bioprinting?
 Who are the leading developers of 4D bioprinters and smart biomaterials?
 Which is the hub of 4D bioprinter and smart biomaterial developers?
 What is the relative competitiveness of different 4D bioprinter and smart biomaterial developers?
 What is the relative competitiveness of different 4D bioprinters?
 What are the strengths and threats for the developers engaged in the 4D bioprinting industry?
 What is the focus of various publications related to 4D bioprinting?
 What is the current / future market of 4D bioprinting?

The financial opportunity within the 4D bioprinting market has been ****yzed across the following segments:
 Type of Technology
 Extrusion-based Technology
 Laser-based Technology
 Inkjet-based Technology
 Others

 Application Area
 Biomedical Applications
 Others

 End-user
 Pharmaceutical and Biotechnology Companies
 Academic Research and Development
 Other end-users

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa

The opinions and insights presented in this report were also influenced by discussions held with eminent stakeholders in this industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
 Suhridh Sundaram (Chief Operating Officer, Avay Biosciences)
 Preethem Srinath (Doctoral Candidate, CURAM)
 Sam Onukuri (Independent Consultant)

The research also includes profiles of key players (listed below) engaged in developing 4D bioprinters and smart biomaterials; each profile features an overview of the company, financial information (if available), details on product portfolio, recent developments, and an informed future outlook.
For additional details, please visit
https://www.roots****ysis.com/....reports/4d-bioprinti
or email [email protected]****ysis.com

The global cell cytometry market is anticipated to grow at a CAGR of ~10%, till 2035, claims Roots Analysis

In order to accommodate the growing demand for higher accuracy, greater resolution and improved sensitivity in ****ytical processes, various industry stakeholders are engaged in the development of novel cytometry platforms with advanced features.
For additional details, please visit https://www.roots****ysis.com/....reports/cell-cytomet or email [email protected]****ysis.com

Digital therapeutics - The regulatory support has facilitated the establishment of a standard developmental pathway
Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions.
For additional details, please visit
https://www.roots****ysis.com/....reports/view_documen or email [email protected]****ysis.com

long-acting drug delivery technologies and services

Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level.
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. In addition, long acting drug delivery formulations can improve the chemical stability, solubility and polymorphic transformation issues of the active pharmaceutical ingredients.

To request a sample copy / brochure of this report, please visit this
https://www.roots****ysis.com/....reports/long-acting-

Lately, many technologies are being explored to develop long-acting drugs in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The long-acting drug delivery technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. Long-acting formulations are more patient compliant, in terms of sharp reduction in the dosing regimen. These drugs are administered infrequently (ranging from once weekly to yearly) owing to the prolonged drug release after a single shot.

The technological advancements for the long-acting profile of the drugs (small molecules, peptides, biologics) have led to the rise in number of novel therapeutics in the market along with the growing number of long-acting molecules in the clinical development pipeline. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. Further, the pharmaceutical industry is extensively focusing on the development of long-acting injectables for protein-based drugs and multidrug therapies. Moreover, the potential of long acting injectables is being explored in several debilitating chronic diseases, such as Alzheimer’s, Parkinson’s disease, blindness and HIV. Owing to the advanced LADD technologies, formulation and developmental challenges ****ociated with these complex dosage forms, the reliability on the stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome.

For additional details, please visit
https://www.roots****ysis.com/....reports/long-acting- or email [email protected]****ysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly ****ytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]****ysis.com

 

www.rootsanalysis.com

Request Sample - Long-Acting Drug Delivery Market | Industry Analysis | Market Size | 2035

Long-acting drug delivery technologies, driven by presence of nearly 100 companies, is anticipated to grow at 13% CAGR

long-acting drug delivery technologies and services | #patient compliance # long acting drug # long-acting drug delivery # long acting injectables # Market Research # Market Insight

News and Politics

long-acting drug delivery technologies and services

Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level.